1999 WHO/ISH hypertension guidelines - Highlights & ESH update

Blood Pressure

Volumn 12, Issue 3, 2003, Pages 181-182

  Kjeldsen, Sverre E ^a   Erdine, Serap ^b   Farsang, Csaba ^c   Sleight, Peter ^d   Mancia, Guiseppe ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Szent Imre Hospital   (Hungary)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FUROSEMIDE; IRBESARTAN; LOSARTAN; NIFEDIPINE; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG TOLERABILITY; EUROPE; FAMILY HISTORY; HEALTH CARE ORGANIZATION; HEART BLOCK; HOME MONITORING; HUMAN; HYPERKALEMIA; HYPERTENSION; LABORATORY TEST; MEDICAL SOCIETY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; PRACTICE GUIDELINES; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 0038446783     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-183.
2. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
3. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
4. Davis BR, Furberg CD, Wright JT, Cutler JA, Alderman M, Black H et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-75.
5. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al. Randomized trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
6. Brown M, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Results of morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356: 366-72.
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.
8. Hansson I, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.
10. Kjeldsen SE, Kolloch RE, Leonetti G, Mallion J-M, Zanchetti A, Elmfeldt D et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000; 18: 629-42.
11. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ 1998;317:703-13.
13. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
15. Bakris GL, Weir MR, DeQuattro V, McMahon G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.